From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Novacyt: a tale of two drunks, a zero one way or another

By Tom Winnifrith, the Sheriff of AIM | Thursday 25 January 2024

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

I suggested that Novacyt (NCYT), of which I have been a perma bear, was doing a bad deal buying Yourgene (YGEN) for £16.7 million in cash. Today’s calendar 2023 trading statement suggests that it had to do some sort of deal as its own business is going nowhere fast. Two drunks can prop each other up for a while but in the end both will collapse into a vomit covered heap anyway.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Which PR genius wrote this?



H&T Group – now again a Buy

Time left: 04:22:09